-
Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes
Wednesday, March 3, 2021 - 10:37am | 310Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (...
-
How Can Cannabis Help With Epilepsy?
Tuesday, November 17, 2020 - 2:44pm | 263This article was originally published on The Medical Cannabis Community, and appears here with permission. CBD is being used more and more to treat Epilepsy. Learn why. In Memory of Charlotte Figi October 18, 2006 – April 7, 2020 Read the original Article on The Medical Cannabis...
-
'Exceeded Our Expectations': First Latin American Study On CBD, Epilepsy Completed
Saturday, December 7, 2019 - 9:50am | 539A research team at Garrahan Children’s Hospital, a public pediatric research hospital in Buenos Aires, Argentina, completed the continent’s first clinical trials on CBD. The study adds overwhelming evidence of the compound’s efficacy in treating refractory epilepsy in children....
-
'Renewed Sense Of Hope': GW Pharma CEO Talks Epilepsy Drug Approval In Europe
Wednesday, September 25, 2019 - 1:59pm | 511Cannabinoid-based drug maker GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) CEO Justin Gover told CNBC's Jim Cramer the company's approval to market Epidiolex across Europe is a "historic milestone" for the field of cannabinoid science. European Approval Epidiolex is the only CBD-...
-
Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study
Thursday, July 12, 2018 - 8:47am | 345Zogenix, Inc. (NASDAQ: ZGNX) peaked nearly 30 percent in Thursday's pre-market session after management released positive top-line results from its second pivotal Phase 3 study of ZX008 in Dravet Syndrome. The trial met primary and secondary endpoints and demonstrated statistical significance...
-
GW Pharmaceuticals' FDA Win Reinforces BofA's Bullish Thesis
Tuesday, June 26, 2018 - 3:50pm | 361The U.S. Food and Drug Administration approval of GW Pharmaceuticals PLC (NASDAQ: GWPH)'s epidiolex therapy for the treatment of seizures was expected — and reinforces the bullish case for owning the stock, according to Bank of America Merrill Lynch. The Analyst Bank of America'...
-
Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation
Wednesday, June 6, 2018 - 3:43pm | 375Marinus Pharmaceuticals Inc (NASDAQ: MRNS) is a developer of ganaxolone, a therapy intended to treat patients with a rare genetic disorder, and initial data is "looking good," according to Ladenburg Thalmann. The Analyst Analyst Michael Higgins initiated coverage of Marinus...
-
'An Incredible Signal': 4 Experts Weigh In On Positive FDA Panel Vote For GW Pharma's Epidiolex
Thursday, April 19, 2018 - 4:37pm | 740Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) were halted Thursday, ahead of a Food and Drug Administration vote on the company's cannabis-derived drug Epidiolex. Trading resumed after the FDA advisory panel voted unanimously in favor of approving the medicine for the treatment of two...
-
Zynerba Pharmaceuticals Volatile After Epilepsy Study Results
Monday, December 4, 2017 - 1:32pm | 571Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday's pre-market session but then sold off after the opening bell. The...
-
What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?
Monday, October 2, 2017 - 1:36pm | 389Zogenix, Inc. (NASDAQ: ZGNX) shares jumped another 5.6 percent Monday morning after exploding higher by 172 percent Sept. 29 in the wake of positive data on anti-epileptic drug ZX008. Shares of GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) plummeted 9.6 percent last Friday as well, and dropped another...
-
What's The Difference Between Zynerba and GW Pharma's Epilepsy Drugs?
Friday, August 18, 2017 - 9:18am | 621The month of August has been hard one for cannabis drug stocks. After Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported a pair of disappointing trial results in its Phase 2 STAR 1 and STOP trials, respectively, the company’s market cap went up in smoke to the tune of a more than 50 percent...
-
What Zynerba's Flop Means For CBD Therapies And GW Pharmaceuticals
Monday, August 7, 2017 - 9:41am | 475Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) lost more than 58 percent of their value Monday morning after the company reported disappointing results from its phase 2 STAR 1 clinical trial for its adult epilepsy treatment. Zynerba is one of the largest cannabinoid-focused pharmaceutical...
-
What Analysts Expect For Zynerba's Upcoming Wave Of Data
Tuesday, August 1, 2017 - 2:00pm | 414Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported Tuesday its second-quarter results along with a series of updates concerning ongoing clinical trials and when investors can expect top-line data. Zynerba was expected to release phase 2 STAR 1 trial data of its ZYN002 for the treatment of adult...
-
Pfizer Fined $106 Million For Anti-Epilepsy Drug
Wednesday, December 7, 2016 - 8:56am | 326Shares of Pfizer Inc. (NYSE: PFE) were little changed after the company said it will appeal a $106 million fine by the United Kingdom's competition regulator, the Competition and Markets Authority (CMA). According to The Wall Street Journal, Pfizer was slapped with a £84.2 million...
-
Oppenheimer Downgrades Marinus Pharmaceuticals, Removes Price Target On Disappointing Epilepsy Study Results
Tuesday, June 14, 2016 - 3:41pm | 196Oppenheimer has downgraded Marinus Pharmaceuticals Inc (NASDAQ: MRNS) to Perform after the company's first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint. Even though company indicated there were certain sub-demographics of better responders in the greater...